Washington, USA
+919405476170
+919405476170

GMP Certified Bevatas Injection Supply for US Market | Ernest Oncology India

Bevatas Injection (Bevacizumab): Targeted Anti-Angiogenic Therapy for Advanced Oncology – Global Supply by Ernest Oncology


In the advanced clinical landscape of 2026, Bevatas Injection (active ingredient Bevacizumab) stands as a pivotal biological therapy for the management of various solid tumors. As a recombinant humanized monoclonal antibody and a highly regulated biosimilar, Bevatas offers a cost-effective yet clinically equivalent alternative to reference biologics, specifically targeting the Vascular Endothelial Growth Factor (VEGF) to inhibit tumor-induced angiogenesis.


Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the GMP-compliant international distribution of Bevatas to London (UK), the United States, Abu Dhabi (UAE), Australia, and South Africa, ensuring rigorous cold-chain management and rapid logistical execution.



Technical Product Information: Bevatas Injection

Bevatas is a sterile, clear to slightly opalescent, colorless to pale brown solution for intravenous (IV) infusion after appropriate dilution.


Product Specifications

  • Active Ingredient: Bevacizumab (Biosimilar)

  • Strengths: 100 mg / 4 mL and 400 mg / 16 mL Single-dose Vials

  • Pharmacological Class: Antineoplastic; Monoclonal Antibody; VEGF Inhibitor

  • Storage Requirements: Store at 2°C to 8°C (36°F to 46°F). Strictly requires validated Cold Chain Logistics. Do not freeze or shake.


Primary Clinical Indications

  1. Metastatic Colorectal Cancer (mCRC): First or second-line treatment in combination with 5-fluorouracil-based chemotherapy.

  2. Non-Small Cell Lung Cancer (NSCLC): First-line treatment of unresectable, locally advanced, or metastatic non-squamous NSCLC.

  3. Glioblastoma: For the treatment of recurrent glioblastoma in adult patients.

  4. Metastatic Renal Cell Carcinoma (mRCC): Used in combination with interferon alfa.

  5. Cervical & Ovarian Cancer: Effective in persistent, recurrent, or metastatic cases when combined with standard chemotherapy protocols.



Mechanism of Action: Arresting Tumor Blood Supply


Bevatas exerts its therapeutic effect by specifically binding to the VEGF protein, preventing it from interacting with its receptors on the surface of endothelial cells.

  • Neutralization of VEGF: By sequestering VEGF, Bevatas prevents the growth signals required for the formation of new blood vessels.

  • Vascular Regression: Existing tumor microvasculature undergoes regression, effectively "starving" the tumor of essential nutrients and oxygen.

  • Normalization of Tumor Vasculature: Bevatas helps normalize remaining tumor vessels, reducing high interstitial fluid pressure and potentially improving the delivery of concurrent chemotherapy.

  • Inhibition of Metastasis: By limiting the vascular network, the drug reduces the pathways through which cancer cells can spread to distant organs.



Global Export Excellence: UK, USA, UAE, Australia, & South Africa


Ernest Oncology manages the logistical complexities of shipping temperature-sensitive biosimilars from India to the world’s most demanding healthcare markets.

  • United Kingdom & London: We supply NHS Trusts and private oncology centers in London, adhering to all MHRA biological import protocols and technical documentation standards.

  • United States: Bulk supply for hospital systems and specialty wholesalers seeking verified Indian pharmaceutical exports for advanced oncology care.

  • Abu Dhabi & UAE: Supporting the UAE’s world-class medical infrastructure with fast-track, secure, temperature-monitored shipping.

  • Australia: Strategic distribution to regional hospitals and wholesalers, maintaining strict compliance with TGA biological import frameworks.

  • South Africa: Strengthening the African oncology sector with high-quality, cost-effective biosimilars from GMP facilities.


📞 Contact Ernest Oncology — Pharmaceutical Exporter from India


(Group of Ernest Pharmaceutical Pvt. Ltd.)

Partner with a verified leader for the bulk procurement of oncology injectables and specialized biological products.

🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com

📧 Email: exports@ernestpharmaceuticals.com 

📦 Business Type: Exporter | Bulk Supplier | Distributor 

📲 WhatsApp: +91 93599 02383 

🔗 Instant Chat: https://wa.me/919359902383

 2026-04-04T09:42:44

Keywords